null

Enfortumab Biosimilar (Anti-Nectin-4) Antibody (HDBS0081)

SKU:
HDBS0081
Antibody Type:
Biosimilar Reference Antibody
Applications:
IHC
FC
Drug Development
Pharmacokinetics
Disease Area:
Cancer
Protein:
NECTIN4
Reactivity:
Human
Host Species:
Humanized
Isotype:
IgG1
$479

Description

system_update_altDatasheet

Enfortumab (Anti-Nectin-4) Biosimilar Antibody (HDBS0081)

The Enfortumab Biosimilar Anti-Nectin-4 Antibody is a cutting-edge therapeutic designed for targeted cancer treatment. This antibody specifically targets the Nectin-4 protein, which is overexpressed in various cancer types, including bladder cancer. By binding to Nectin-4, this antibody blocks its function, inhibiting cancer cell growth and promoting cell death.Developed as a biosimilar to enfortumab vedotin, a promising cancer treatment, this antibody offers a more cost-effective and accessible option for patients in need.

Its efficacy has been validated in preclinical studies, demonstrating significant tumor regression and improved survival rates in animal models.With the potential to revolutionize cancer treatment, the Enfortumab Biosimilar Anti-Nectin-4 Antibody holds promise for patients seeking new and effective therapeutic options. Its targeted approach and proven efficacy make it a valuable asset in the fight against cancer.